Gadolinium enhanced coronary angiography in patients with impaired renal function: A pilot study  by Sarkis, Antoine S. et al.
JACC March 19,203 ABSTRACTS - Angiography & Interventional Cardiology 63A 
Age Contrast (ml) Diabetes Mean EF (%) Mean ECC CIN 
(Y) mllmin 
NAC 73+8 151*49 35% 52 37 0 
N= 46 
Control 75+6 164+67 34% 51 41 6 
N=137 (6.6%) 
P “S “S “S “S <O.OOl <0.00001 
Conclusions: There was no incidence of CIN in the patients receiving NAC despite a 
lower ECC compared to the control group. Oral administration of NAG immediately prior 
to PCP appears to ameliorate CIN in patients with ECC < 50mllmin. A larger randomized 
prospective study is required to validate the utility of this new strategy. 
1174-189 Tirofiban Does Not Attenuate the Acute Inflammatory 
Response Triggered by Percutaneous Coronary 
Interventions 
Rabih R. Azar, Georges Badaoui, Antoine Sarkis. Charbel Medawar, Samira Klayme, 
Myrna Genanos, Roger Naaman, Hotel Dieu de France Hospital, Beirut, Lebanon 
Background: Percutaneous coronary intewention (PCI) triggers an inflammatory 
response which is incriminated in the pathogenesis of future adverse cardiac events. 
Tirofiban improves the outcome of PCI by inhibiting platelets aggregation, but its effect 
on the inflammatory response remains unknown. Methods: Patients with stable coronaty 
artery disease and no known inflammatory conditions who were undergoing PCI, were 
randomized to receive a bolus and a 24-hour infusion of tirofiban vs. saline. High sensi- 
tivity C-reactive protein (hs-CRP). interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), 
and soluble intracellular adhesion molecules @ICAM) were measured at baseline and 46 
hours after the procedure. Fleeufts: Forty patients were enmlled, 21 in the tirofiban group 
and 19 in the saline group. Stenting was performed in all but 1 patient who had balloon 
angioplasty. Troponin T was undetectable in all patients at baseline and 24 hours later. 
Levels of hs-CRP, IL-6, and TNF increased following PCI (h&RF? 9.li13.6 mg/dL vs. 
16.5il5.5 mg/dL, p<O.OOl; IL-6: 4.4g.4 pg/mL vs. 6.324.5 pg/mL, p=O.Ol; TNF: 4.722 
pg/mL vs. 7.3i10.4 pg/mL. p=O.O9). Levels of slCAM did not change (214110 ng/mL vs. 
221 fl0 ng/mL, p=NS). None of the changes in the 4 markers was significantly affected 
by the use of tirofiban (table). Conclusion: hs-CRP, IL-6 (and probably TNF) but not 
slCAM are increased 46 hours after PCI. This acute inflammatory response however, is 
not attenuated by the use of tirofiban. 
Tirotiban 
Saline 
P value 
1174-190 
Markers’ mean changes. Data are expressed as mean +I- SD 
hs-CRP (mg/dL) IL-6 @@ml) TNF (pg/mL) &CAM (ng/mL) 
10.*11.9 2.7+5 4.2~12.3 -1+24 
7.7+8.5 0.923.5 0.9&4.6 wJ 
NS NS NS NS 
Elective Coronary Angioplasty and Percutaneous 
Coronary Intervention During Uninterrupted Warfarin 
Therapy 
David B. J~SSUD, Andrew T. Coletti, J. Brent Muhlestein, William H. Ban-y, Fredric C. 
Shean, Brian K. Whisenant, University of Utah, Salt Lake City, UT, LDS Hospital, Salt 
Lake City, UT 
Background: The management of patients anticoagulated with warfarin and referred for 
coronary angiography presents a substantial challenge to the physician who must bal- 
ance the risks of periprocedural hemorrhage with thromboembolism. The aim of this 
study was to evaluate the feasibility and safety of diagnostic coronary angiography and 
percutaneous coronary intewention (PCI) during uninterrupted watfarin therapy. 
Methods: Patients treated with wadarin were prospectively identified and enrolled in the 
study. Coronary angiography was performed in the usual fashion using a femoral 
approach without interrupting warfarin. PCI was performed as clinically indicated. 
Results: Nineteen diagnostic cardiac catheterizations and 6 percutaneous coronary 
interventions were performed in 23 patients. The mean age was 72 (+/-9) years and 12 
(52%) were male. The primary indication for anticoagulation was atria1 fibrillation in 11 
(46%), mechanical valve in 5 (22%). deep venous thrombosis in 5 (22%) and stroke in 2 
(9%). The mean international normalized ratio (INR) was 2.4 (+/-0.5, range 1.6-3.5). The 
primaty indication for catheterization was acute coronary syndrome in 16 (64%). elective 
coronary evaluation in 4 (16%), valvular heart disease in 2 (8%), congestive heart failure 
in 2 (6%) and atrial septal defect in 1 (4%). Seventeen (68%) procedures were performed 
during inpatient hospitalization. Venous sheaths were used in 10 (44%) procedures. 
Hemostasis was achieved with the AngioSeal device following 21 (64%) procedures and 
with the Perclose device following 4 (16%) procedures. No patient experienced a pre- 
defined endpoint. Specifically, no patient experienced procedure related myocardial inf- 
arction, TIMI major or minor bleeding, or hemodynamic compromise. There were no 
hematomas greater than 5 cm in diameter, and no incidences of vascular injury including 
pseudoaneurysm or AV fistula. 
Conclusions: Cardiac catheterization and percutaneous coronary intewention may be 
considered in the sening of uninterrupted warfarin therapy. 
1174-191 The Influence of Baseline Thrombocytopenia on the 
Outcomes of Percutaneous Coronary Interventions 
Pertha S. Chowdhuy, Razvan M. Chirila. Saroj K. Chowdhury, Judith A. Boura, William 
W. ONeill, William H. Devlin, William Beaumont Hospital, Royal Oak, Ml 
Background:Questions have arisen regarding the safety of performing PCI on patients 
with low platelet (pit) counts on admission, as there are few data regarding this issue. 
This study examined clinical outcomes in patients who had thrombocytopenia at presen- 
tation and then underwent PCI. 
Methods: We studied 195 patients with admission plt counts of 5 150,000 and who had 
PCI at William Beaumont Hospital from 1993 to 2OOQ A control group (N=216) that had 
PCI during the same time period and had normal plt counts was randomly chosen. Pro- 
spectively collected in-hospital clinical outcomes (bleeding complications, reinfarction, 
stroke and death) were compared between the two groups. 
Results: Mean plt counts were: study group (10+30K) and control (20+5OK). The two 
groups had no differences in gender, histoly of smoking, diabetes, ulcer disease, or renal 
failure. The study group received more heparin post-PC1 (19 vs 10%) and GP2b3a inhib- 
itors (23 vs 13%) (p<O.O5). Thrombocytopenic patients, compared to control, had similar 
rates of reinfarction (2.6 vs 2.6%. p=l.O), stroke (1 vs 0%. p=O.225), and death (3.6 vs 
0.9%. p=O.O92). Bleeding complications were higher in the study group with more groin 
hematomas (25 vs 15%, p=O.O16) and transfusions (13 vs 3%, p<O.OOOl). Neither group 
had any retroperitoneal bleeding. There was no difference in CNS bleeding (0.5 vs O%, 
~~0.475). Other bleeding did occur more frequently in the study group (6.0 vs 1.4%, 
p=O.O16). Further analysis of patients with plt counts < 100,OM) (N=77. mean count: 
73j3K) showed similar outcomes. Multivariate analysis showed that plt count < 150K 
independently predicted groin hematoma (OR=2.05, p=O.OOS) and need for transfusion 
(OR=5.69, p=O.O007). 
Conclusions: To our knowledge, this study is the first to demonstrate that PCI in 
patients with thrombocytopenia on presentation can be pelformed relatively safely as 
there is no difference in reinfarction, stroke, and death compared to patients with normal 
platelet counts. An increased bleeding risk was manifested in groin hematomas and an 
increased need for transfusion. This suggests that, although PCI is safe, caution should 
be used in these patients. 
1174-192 Hydration Versus N-Acetylcysteine for Protection of 
Renal Function in Patients With Renal Insufficiency 
Undergoing Percutaneous Coronary Intervention 
Anne S. Kanderian. Raed H. Abdelhadi, Deepak L. Bhatt, Jakob Schneider, Mina K. 
Chung, The Cleveland Clinic Foundation, Cleveland, OH 
Background: Patients with renal insufficiency are at higher risk for renal worsening aHer 
percutaneous coronary intervention (PCI). The efficacy of N-acetylcysteine (NAC) in pre- 
venting renal failure in patients undergoing PCI is controversial. 
Methods: From a clinical and research database of PCI (Jan 2OOOJuly 2002) and chalt 
reviews, patients with renal insufficiency (creatinine~l.2mg/dl and/or estimated creati- 
nine clearance<60ml/min) were identified. Nonionic contrast dye was employed during 
PCI. Changes in serum creatinine concentration 24-26 hours after PCI were compared in 
those patients who received NAC and hydration, hydration alone, and in those who 
received neither. Data were analyzed using Student’s t-tests. 
Results: Of 65 patients with renal insufficiency and who had baseline and follow up cre- 
atinine levels, NAC and hydration were used in 26 (mean creatinine prior to PCI 2.4Ql.5 
mgldl compared to 3.4122.73 mgldl in those who did not receive NAC,p=O.O9). 26 of 
patients received hydration alone, and 29 had neither NAC nor hydration. The mean cre- 
atinine decreased by 0.06$39 mgidl in patients who received NAC and hydration com- 
pared to an increase of 0.5&l .36 mg/dl in patients who did not receive either,p=0.031. 
In patients who received hydration alone, the mean creatinine decreased by 0.13$0.40 
mg/dl,p=0.015. However, there was no statistical significance in patients who received 
NAC and hydration compared to those who only received hydration.p=0.46. 
Conclusion: In patients with chronic renal insufficiency undergoing PCI, the use of NAC 
along with hydration, and hydration alone were both associated with a significant protec- 
tion of renal function. There was no statistical significance in protection of renal function 
in patients who had NAC and hydration compared to hydration alone. A prospective ran- 
domization of NAC in addition to hydration is warranted to determine whether there is 
additional benefit of NAC in PCI. 
1174-193 Gadolinium Enhanced Coronary Angiography In 
Patients With Impaired Renal Function: A Pllot Study 
Antoine S. Sarkis Georges Badaoui. Rabih R. Azar, Ghassan Sleilaty, Rania Bassil, 
Victor A. Jebara, Hotel Dieu de France Hospital, Achrafieh, Lebanon 
Backgrounct Deterioration of renal function is a major concern in predisposed patients 
undergoing coronary angiography. Gadolinium is a contrast agent, used routinely for 
magnetic resonance imaging. It is safe and has shown no nephrotoxicity. However, sig- 
nificant limitations in image quality are encountered when this drug is used alone, even at 
the maximum recommended dose. The aim of this prospective pilot study was to evalu- 
ate the efficacy and the safety of Gadolinium enhanced with low-dose non-ionic contrast 
agent for coronary angiography in patients with impaired renal function. Methods: We 
performed coronary angiography in 15 patients at high-risk for renal failure by mixing 
gadolinium with a small quantity of non-ionic contrast agent.Results: The mean volume 
of Gadolinium used per patient was 44 mL (0.6 + 0.2 mUkg of body weight) and the 
mean volume of non-ionic contrast agent was 22 mL (0.322 0.2 mUkg of body weight). 
Good quality images were obtained in all cases. Renal function tests remained 
unchanged before and after the procedure. Mean pre-procedural and post-procedural 
serum creatinine were 22&66 micromol/L and 216&77 micromolll, respectively 
(p=O.36). Mean pre-procedural and post-procedural creatlnine clearance were 2%6 mU 
min and 31210 mUmin, respectively (~~0.36). No adverse cardiac effects were 
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observed: there were no arrhythmias, no conduction disturbances and no ST-segment 
modifications. Cardiac enzymes remained unchanged. Conclusion: Gadolinium 
enhanced coronary angiography is safe and well tolerated. The mixture of Gadolinium 
with non-ionic contrast allowed us to obtain diagnostic angiograms of excellent quality in 
all cases. In patients at high-risk for renal failure, Gadolinium constitutes an interesting 
adjunct to contrast agents for coronary artery imaging. 
1174-194 Nicorandil, a KATp Channel Opener, Facilitates the 
Recovery of Ventricular Contraction After Reperfusion 
Therapy in Acute Myocardial Infarction: Multicenter 
Registry in Japan 
Sunao Nakamura, Eita Saito, Takanori Miyauchi. Jin Yokoyama, Akihiko Kanazawa. 
Yasufumi Hayama, Koji Hozawa, Shotaro Nakamura, Hitoshi Nakamura, Kazutoshi 
Yamamoto, New Tokyo Hospital, Matsudo-shi, Japan, Kasori Hospital, Chiba-shi, Japan 
To clanfy whether Nicorandil (N) given after acute myccardial infarction (AMI) affects 
subsequent changes in contractile function, we randomized 209 consecutive AMI 
patients hospitalized within 6 hours and gave them either an i.v. drip infusion of 6 mgi 
hour of N (n = 107) or normal saline (S) as control (n = 102) (double blind controlled 
NIMIS trial). No differences existed between the groups in terms of age and gender; 
severity of AMI was also the same as determined by Killip or Forrester classification and 
the left ventriculogram (LVG). One hour before the reperfusion therapy, i.v. infuwn of N 
or S was started and LVG were recorded, as baseline data. Two weeks, 3 months and 
one year later, we repeated the Same tests and compared the results with the baseline 
data. 
Results: The incidence of ventricular arrhythmias (PVCs, VT) and global ejection frac- 
tion were not significantly changed between the groups. However, the regional wall 
motion determined by centerline method after reperfusion therapy was significantly 
greater in N than S group (Figure) and one year cardiac event fee rate was also smaller 
than in N than S group. 
Conclusion: Results suggest that Nicorandil facilitates the recovery of left ventricular 
contractile force in AMI pabents who underwent repeffusion therapy within 6 hours after 
the onset. 
40s 
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1174-195 Is Insulin Resistance Associated With One-Year Target 
Vessel Revascularization Rates Results From CREDO 
IRS? 
Steven Marso, Ellen S. McErlean, Eric J. Topol, Steven R. Stelnhubl, Mid America Heart 
Institute, Kansas City, MO 
Insulin Resistance Syndrome (IRS) has been linked with increased neointimal prolifera- 
tion and target vessel revascularization rates in animal models and small human studies. 
CREDO IRS sought to compare one-year target vessel revascularization rates among 
non-diabetic patients undergoing PCI stratified by Homeostasls Model Assessment 
(HOMA). CREDO is a prospective multi-center randomized controlled trial enrolling 
patients undergoing PCI. Patients were randomized to a standard therapy: loading dose 
of placebo and aspirin 325 mg 3.24 hours prior to PCI, 75 mg of clopidogtel within 1 hour 
of PCI. aspirin and clopidogrel 2-26 days, placebo and aspirin 29-365 days, or an 
aggresswe regimen: a loading dose of clopidogrel 300 mg and aspirin 325 mg, 3-24 
hours prior to PCI. 75 mg of clopidog.el within 1 hour of PCI, aspirin and clopidogrel 2- 
365 days. CREDO-IRS was a prospectively designed sub-study. Fasting levels of insulin 
and glucose where measured. Insulin resistance was determined by HOMA tertles. The 
primary endpoint for CREDO-IRS was the need for l-year target vessel revasculawa- 
tion. Other endpoints included the combined’rate of death, MI or revascularization. There 
were 726 patients without a history of type 2 DM eligible for comparison within CREDO 
IRS. These patients were stratified, based on HOMA tertiles. The 26.day events are 
depicted in the table below. The one-year results will be available for presentation. 
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28.Day Events - HOMA Tertiles 
cl.69 1.89-3.36 >3.38 P-value 
N 242 242 242 
DeathlMliUTVR (%) 9.5 7.4 6.3 0.72 
Death (all cause. %) 0.4 0.0 0.0 
Myocardial Infarction (%) 7.4 6.6 7.4 
QMI (%) 1.2 0.8 1.2 
NQM (%) 6.2 5.6 6.2 
Urgent TVR (%) 1.7 0.6 0.8 
1174-196 Temporal Trends of One-Year Reinfarction and Mortality 
Rates Following Primary Angioplasty in High-Risk 
Acute Myocardial Infarction Patients 
Beth A. Bartholomew, Kishore J. Harjai. Judith A. Boura, Srinivas Dukkipati, Michael W. 
Yerkey, Lorelei L. Grines, Bruce R. Brodie, David Cox, Gregg W. Stone, William W. 
O’Neill, Cindy L. Grines, William Beaumont Hospital, Royal Oak, Ml 
Background: The use of primary angioplasty as treatment for acute myocardial infarction 
(AMI) is well established and use has tripled over the last decade. Numerous therapeutic 
advances have been introduced. However, no data exists regarding trends in adverse 
events and long term outcomes for high nsk AMI patients. Methods: Of the 3755 AMI 
patients who had PCI enrolled in the Primary Angioplasty in Myocardial Infarction (PAMI) 
studies from 1990-‘99, 1867 were high risk: heart rate >lOO, anterior infarct, LBBB, sys- 
tolic BP<100 and age over 70. The patients were grouped into 2 ttme periods: ‘90.‘94 
(n=607) and ‘95-‘99 (n=1364). Comparisons of 1 year reinfarction (1 yr reMI) and death 
rates were made between the 2 periods. Reinfarction was defined as recurrent symp- 
toms with any increase in creatine klnase MB fraction above its previous nadir. Multivari- 
ate regression analysis evaluating age >70, gender, EF, Kill@ class >l, systolic BPclOO, 
prior MI, stent use. final stenosis, final dissection, 3 vessel disease, smoking status and 
year enrolled, was used to determine the strongest predictors of 1 yr reMI. Results: 1 yr 
reMl and mortality rates are shown in the table. Year prior to 1995(p<O.O001. OR 3.96) 
and three vessel disease (p-zO.0029, OR 2.06), but not stent use, were independent pre- 
dictors of 1 yr reMI. Conclusions: High risk AMI patients treated with PCI have had a 3 
fold reduction in 1 yr reMl without change in mortality. This is likely attributable to 
improved secondary prevention strategies. 
Reinfarction 
Modality 
‘90.‘94 
9.7% 
6.9% 
‘95.‘99 
2.8% 
8.x 
P value 
<0.0001 
0.12 
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1175-178 Preinterventional Levels of C-Reactive Protein and 
Platelet Function in Patients With Stable Angina 
Nicolas van Beckerath, Olga Gorchakova, Meinrad Gawaz. Julinda Mehilli, Alban Dibra, 
Albert Schomig, Adnan Kastrati, TU Miinchen, Munich, Germany 
Background: Elevated plasma levels of C-reactive protein (CRP) are associated with an 
increased risk of cardiovascular events. Recently, it has been shown that this is alsO true 
for patients with acute coronary syndromes undergoing percutaneous coronary revascu- 
larization. In vitro studies have shown that CRP itself may influence platelet function. 
Methods: Citrated blood samples from 305 consecutive patients with stable angina were 
obtained from the arterial sheath before coronary stenting. All patients had received aspi- 
rin and a loading dose (600 mg) of clopidogrel. CRP plasma levels were determined with 
a high sensitivity assay. Platelet aggregation !n response to ADP, collagen and throm- 
bine activating peptide (TRAP) was measured with lumi-aggregometry, surface expres- 
sion of membrane receptors with flow-cytometry. 
Results: Patients were divided in two groups: CRP > 5 mg/L (n=144) and CRP 6 5m& 
(n=l61). Maximum aggregation (maximum Increase of light transmissvx) in response to 
ADP (5 and 20pM). collagen and TRAP did not differ between the two groups (P values 
0.54, 0.90, 0.40 and 0.83 respectively). In addition, elevated CRP levels were not associ- 
